Government approves introduction of bills aimed at securing TRIPS compliance and stiffen penalties for drug counterfeiting.
In a case likely to have far-reaching implications for settlements of patent litigation in the pharmaceutical industry, the FTC says three drug makers colluded to keep a generic off the market.
Court rules two products by Boston Scientific infringe a patent by Medinol, but imposes minimal restrictions on sales.
Lawsuits resulting from Barr's Abbreviated New Drug Application for a generic version of hyperactivity drug Adderall XR have been consolidated.
The European Parliament adopts sweeping new legislation aimed at standardizing regulatory data protection for drugs across the European Union.
Another setback for Cellergy, which was forced to pull its NDA for the treatment last year and was sued over a licensing agreement last week.
The U.S. District Court for the Southern District of New York again extended the restraining order to prevent Eon Labs from introducing Bupropion, the generic equivalent of GlaxoSmithKline’s antidepressant Wellbutrin.
Courts in Europe and the U.S. dealt further setbacks for AstraZeneca’s efforts to extend patent rights to an ulcer treatment that was once the world’s best-selling drug.
University claims AMDL induced researcher to sell combination immunogene therapy technology in violation of patent policy.
Irish drug maker says move follows termination of an agreement with Pfizer to jointly develop research into treating Alzheimer's disease.
Even as Pennie & Edmonds is shutting down, Pfizer and the University of Rochester are taking the firm to court over alleged ethical breaches next week.
Out-of-court settlement yields licensing agreements with several local drug makers.
Bausch & Lomb received patent for anti-oxidant and mineral formula Tuesday morning and filed the lawsuits immediately afterward.
Bill would extend pharma patents but would leave rules on compulsory licensing and patentability intact, sources say.
Brazilian government continues to play hardball with HIV/AIDS drug makers after winning record discount from Bristol-Myers Squibb last month.
Senate vote on spending bill with provision banning human-organism patents could be delayed until late January.
Suit alleges that ADM and Amerifit infringed on Solae's patents for soy isoflavone health supplements.
Generic drugmaker eyes hormone therapy with sales of $16 million per year.
Legal battle for antidepressant blockbuster heats up as Andrx gets restraining order on ANDA approval for drug contested by GlaxoSmithKline and Eon Labs.
AMO sues for infringement of patents for technologies used in eye surgery.